Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587342 | 0.91 | BTN3A1 (0.57) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL21158058 | 0.91 | BTN3A1 (0.55) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL21158529 | 0.91 | BTN3A1 (0.55) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL18256378 | 0.91 | BTN3A1 (0.57) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL16587336 | 0.91 | BTN3A1 (0.57) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL16587340 | 0.90 | BTN3A1 (0.65) | BTN3A1LMNAANPEPLAP3MEN1 | |
| SCHEMBL15763390 | 0.86 | BTN3A1 (0.47) | BTN3A1LMNAPRTN3MEN1KMT2A | |
| SCHEMBL16587348 | 0.84 | BTN3A1 (0.49) | BTN3A1LMNAPRTN3 | |
| SCHEMBL16587345 | 0.84 | BTN3A1 (0.49) | BTN3A1LMNAPRTN3 | |
| SCHEMBL16587346 | 0.84 | BTN3A1 (0.49) | BTN3A1LMNAPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9296779-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885PRTN3 1576/4885 |
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885LMNA 1511/4885PRTN3 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.